Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | CDK8 | P49336 | 8/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.42 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12355382 | 0.83 | HRH3 (0.50) | MAOBALDH1A1CDK8 | |
| SCHEMBL2417239 | 0.83 | P4HTM (0.51) | MAOBP4HTMALDH1A1MAPTMEN1 | |
| SCHEMBL5755276 | 0.82 | P4HTM (0.63) | P4HTMALDH1A1AKR1C3P4HA1MIF | |
| SCHEMBL11412089 | 0.82 | HRH3 (0.54) | P4HTMCDK8 | |
| Hydrochloric Acid SCHEMBL11410315 | 0.81 | P4HTM (0.50) | MAOBP4HTMALDH1A1MAPTMEN1 | |
| SCHEMBL3409437 | 0.81 | MAOB (0.54) | MAOBALDH1A1ATMMAPTSMN1; SMN2 | |
| SCHEMBL5636376 | 0.80 | MAOB (0.50) | MAOBALDH1A1ATMCDK8MAPT | |
| SCHEMBL11412080 | 0.79 | CDK8 (0.55) | ALDH1A1CDK8MAPTGAAPOLB | |
| SCHEMBL2029669 | 0.78 | P4HTM (0.44) | P4HTMALDH1A1CDK8P4HA1MIF | |
| SCHEMBL19405836 | 0.78 | P4HTM (0.74) | MAOBP4HTMMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641759-B1 | MALONAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-03-12 | — | — | EP | disclosed |
| EP-1643991-B1 | BENZIMIDAZOLE CARBOXAMIDES AS RAF KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2014-03-12 | — | — | EP | disclosed |
| US-7691870-B2 | Benzimidazole carboxamides as raf kinase inhibitors | MERCK PATENT GMBH (DE) | 2010-04-06 | — | — | US | disclosed |
| US-20070213374-A1 | Malonamide Derivatives | MERCK PATENT GMBH (DE) | 2007-09-13 | — | — | US | disclosed |
| US-20070093532-A1 | Benzimidazole carboxamides as raf kinase inhibitors | MERCK PATENT GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| US-20060189665-A1 | Oxamide derivatives useful as raf-kinase inhibitors | MERCK PATENT GMBH (DE) | 2006-08-24 | — | — | US | disclosed |
| EP-1643991-A1 | BENZIMIDAZOLE CARBOXAMIDES AS RAF KINASE INHIBITORS | MERCK PATENT GmbH (DE) | 2006-04-12 | — | — | EP | disclosed |
| EP-1641759-A2 | MALONAMIDE DERIVATIVES | MERCK PATENT GmbH (DE) | 2006-04-05 | — | — | EP | disclosed |
| EP-1606260-A1 | OXAMIDE DERIVATIVES USEFUL AS RAF-KINASE INHIBITORS | MERCK PATENT GmbH (DE) | 2005-12-21 | — | — | EP | disclosed |
| WO-2005005389-A2 | MALONAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2005-01-20 | — | — | WO | disclosed |
| WO-2005004863-A1 | BENZIMIDAZOLE CARBOXAMIDES AS RAF KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2005-01-20 | — | — | WO | disclosed |
| WO-2004085399-A1 | OXAMIDE DERIVATIVES USEFUL AS RAF-KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093532-A1 | Benzimidazole carboxamides as raf kinase inhibitors | BRAF, RAF1, ARAF | MAOB 1920/4885P4HTM 2771/4885ALDH1A1 1318/4885 |
| US-20060189665-A1 | Oxamide derivatives useful as raf-kinase inhibitors | BRAF, RAF1, ARAF | MAOB 910/4885P4HTM 2635/4885ALDH1A1 921/4885 |
| US-20070213374-A1 | Malonamide Derivatives | RAF1, BRAF, ARAF | MAOB 383/4885P4HTM 3632/4885ALDH1A1 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.